Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Gotta love the... huh?s ...in this article...
View:
Post by rgonlyfactspls on Nov 22, 2015 11:35am

Gotta love the... huh?s ...in this article...

I know article/link below (re: Cantech letter/ Loe) has been posted, but it brought two things to mind.... First, If AdCom participant not convinced by the data (concerned about "some" of the data's shortcomings), yet seeing overwhelming positive safety data and MCNA still "directionally" effective.... wouldn't the appropriate choice be to ABSTAIN from the vote??? If the participant believes the shortcoming(s) in the data mean there is not enough evidence/proof to warrant a YES vote, using the same logic, doesn't this also imply (logically) there is not enough proof to warrant/ BE SURE of a NO vote is justified (particularly in light of other findings shown)?? Of course forget "need" all together as not part of the question of benefit vs risk. An ABSTAIN still sends a message and discussion/feedback already noted/has taken place. --- Second, refers to Loe's new 1-yr price target in article per quote --- "In a research update to clients today, Loe downgraded Telesta Therapeutics from Speculative Buy to Hold and cut his one-year price target from $1.70 to $0.30". I would add a HUH?? to Loe's $.30 "1-YEAR TARGET unless a complete "cover your butt"...just like many at the AdCom. There was no mention in article AdCom "vote" and discussion/feedback IS ONLY "ADVICE" to the FDA. The FDA approval or not for MCNA is still FAR FROM OVER. IMHO https://www.cantechletter.com/2015/11/telesta-therapeutics-gets-price-target-slashed-at-euro-pacific/
Comment by thathurt on Nov 22, 2015 12:03pm
rg, IMO members are expected to vote, and it is Advisory not binding or mandatory or whatever..FDA can ignore or support vote as they see fit... ..IMO folks are paying too much attention to previous stuff where stats are quoted of FDA approving or not consistent with the AdCom vote..and i will address from a couple of points of view: a) there a relatively few votes per year and in cancer area ...more  
Comment by DamnYankees on Nov 22, 2015 12:27pm
You think Euro pac clients were net buyers or sellers since Thursday? Got a feeling they are going to be a hungry fat kid in the middle of a Burger King looting. But it won't be telegraphed by said analyst. he's a cagey fellow.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities